Background. Although not guideline recommended, studies suggest 50% of locoregional breast cancer patients undergo systemic imaging during follow-up, prompting its inclusion as a Choosing Wisely measure of potential overuse. Most studies rely on administrative data that cannot delineate scan intent (prompted by signs/symptoms vs. asymptomatic surveillance). This is a critical gap as intent is the only way to distinguish overuse from appropriate care. Objective. Our aim was to assess surveillance systemic imaging post-breast cancer treatment in a national sample accounting for scan intent. Results. Of 10,838 women, 30% had one or more, and 12% had two or more, systemic surveillance scans during a 4-year follow-up period. Patients were more likely to receive surveillance imaging in the first follow-up year (lower proportions during subsequent years) and if they had estrogen receptor/progesterone receptor-negative tumors. Conclusions. Locoregional breast cancer patients undergo asymptomatic systemic imaging during follow-up despite guidelines recommending against it, but at lower rates than previously reported. Providers appear to use factors that confer increased recurrence risk to tailor decisions about systemic surveillance imaging, perhaps reflecting limitations of data on which current guidelines are based. ClinicalTrials.gov Identifier: NCT02171078.
ABSTRACT
Background. Although not guideline recommended, studies suggest 50% of locoregional breast cancer patients undergo systemic imaging during follow-up, prompting its inclusion as a Choosing Wisely measure of potential overuse. Most studies rely on administrative data that cannot delineate scan intent (prompted by signs/symptoms vs. asymptomatic surveillance). This is a critical gap as intent is the only way to distinguish overuse from appropriate care. Objective. Our aim was to assess surveillance systemic imaging post-breast cancer treatment in a national sample accounting for scan intent. Methods. A stage-stratified random sample of 10 women with stage II-III breast cancer in 2006-2007 was selected from each of 1217 Commission on Cancer-accredited facilities, for a total of 10,838 patients. Registrars abstracted scan type (computed tomography [CT] , non-breast magnetic resonance imaging, bone scan, positron emission tomography/CT) and intent (cancer-related vs. not, asymptomatic surveillance vs. not) from medical records for 5 years postdiagnosis. Data were merged with each patient's corresponding National Cancer Database record, containing sociodemographic and tumor/treatment information. Results. Of 10,838 women, 30% had one or more, and 12% had two or more, systemic surveillance scans during a 4-year follow-up period. Patients were more likely to receive surveillance imaging in the first follow-up year (lower proportions during subsequent years) and if they had estrogen receptor/progesterone receptor-negative tumors. Conclusions. Locoregional breast cancer patients undergo asymptomatic systemic imaging during follow-up despite guidelines recommending against it, but at lower rates than previously reported. Providers appear to use factors that confer increased recurrence risk to tailor decisions about systemic surveillance imaging, perhaps reflecting limitations of data on which current guidelines are based. ClinicalTrials.gov Identifier: NCT02171078.
Improvements in early detection and treatment of locoregional breast cancer have increased the 5-year survival rate to 90%. Over 3 million breast cancer survivors receive follow-up care in the US. [1] [2] [3] Clinical guidelines published by the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network recommend frequent clinical follow-up visits to detect new primary cancers, recurrence, and treatment side effects. However, guidelines specifically recommend against asymptomatic systemic imaging for surveillance of metastatic disease, with systemic imaging only recommended in the presence of suspicious signs or symptoms. [4] [5] [6] Despite clinical practice guidelines, population-level studies suggest significant overuse of systemic imaging following breast cancer treatment. In these studies, nearly half of all patients with locoregional breast cancer undergo at least one systemic imaging study ( However, population-level studies to date have primarily relied on administrative data that are unable to differentiate between imaging prompted by a patient symptom or clinical sign, and asymptomatic surveillance. Without such information, it is impossible to distinguish true overuse from guideline-concordant imaging due to signs or symptoms. Consequently, claims-based studies may overestimate systemic imaging use for routine surveillance. Furthermore, administrative data are unable to evaluate whether tumor characteristics, and therefore recurrence risk, are driving observed utilization patterns. We sought to address these gaps using abstracted medical records from a national sample of women with breast cancer diagnosed at 1217 facilities.
METHODS

Setting and Population
This study used a national cancer registry augmented with primary data collection. The National Cancer Database (NCDB), 13, 14 a joint program of the American College of Surgeons, Commission on Cancer (CoC), and the American Cancer Society, captures 70% of newly diagnosed cancers in the US. 13, 15 To maintain accreditation and ensure data quality, facilities are required to follow 90% of patients from diagnosis until death, regardless of where patients receive follow-up care. Using a standardized abstraction manual, trained registrars collect information on sociodemographic, tumor, and treatment factors. 16 Imaging and recurrence were abstracted to supplement standard elements as part of a special study initiative. Only de-identified data were provided to investigators and therefore the study was deemed exempt as non-human subjects research by the University of Wisconsin Institutional Review Board.
Eligibility Criteria and Sampling Strategy
Women over age 18 years were eligible if they had a first diagnosis of stage II-III breast cancer (International Classification of Diseases for Oncology, Third Edition, code C50.0-C50.9) in 2006-2007. These years were selected to allow follow-up through 2013, the most recent data available. Such patients, who were treated with curative intent (including surgery), were considered most likely to undergo systemic imaging because they are at higher risk of recurrence than women diagnosed at earlier stages (0-I).
A stage-stratified random sample of up to 10 patients (7 stage II, and 3 stage III) was selected from all 1231 facilities accredited by the CoC in 2006-2007 (n = 11,478). We sought to maximize generalizability by randomly selecting a small number of patients at all CoC institutions. The sampling strategy was designed to achieve a similar ratio of stage II to stage III patients as observed nationally (for census of patients meeting the inclusion criteria, 73.9% were stage II and 26.1% were stage III in the NCDB), while minimizing abstraction burden. Overall, 1217 facilities participated (99%), with 11,360 patient records submitted. All but 17 facilities diagnosed and treated at least one stage III patient.
Trained facility registrars solicited and reviewed relevant patient records from their own and outside facilities, beginning at the end of active treatment (approximated by 10 months post-diagnosis) and continuing until (1) the end of the fifth year post-diagnosis, (2) distant recurrence, or (3) death, whichever was first. Follow-up information, including systemic imaging (CT, MRI, bone scan, PET) was abstracted using a standardized abstraction manual and entered via a secure web platform. The type and indication of each imaging study was recorded, along with date performed and results. HER2neu status, not abstracted routinely in 2006-2007, was also collected. Key fields (e.g. date of death) were confirmed. Registrars abstracted recurrence because this element is unreliable and was missing for 20% of patients. 17 Recorded data elements were merged with a patient's corresponding record in the NCDB.
Patients were excluded if they had delayed surgery ([ 1 year from diagnosis, n = 17) or had recurrence, new primary cancer, death, or were lost to follow-up before the start of the surveillance period (10 months from diagnosis) [n = 505].
Surveillance Imaging
Systemic scans were grouped into three categories according to the area imaged: bone scans, body imaging (non-breast MRI, CT, and/or PET of the chest, abdomen, and/or pelvis), and brain imaging (CT and MRI). Imaging was considered surveillance if classified as 'surveillance imaging in the absence of new signs or symptoms (asymptomatic)'. Registrars were guided to high-yield locations in the medical record to obtain this information (primary: radiology/imaging reports from their own/other institutions; secondary: notes from clinic and consult visits from primary care, oncologist, or other providers, paying particular attention to references to symptoms or instructions to schedule scans within a specified time period). Often, multiple data sources were combined to evaluate a given imaging study. In order to compare with previous studies, a composite variable-'cancer-related scans'-included surveillance scans and scans with the following clinical indications: follow-up for new sign/symptom; follow-up for suspicious finding on other imaging; imaging performed as part of staging work-up for newly detected malignancy (new primary or recurrence).
Sociodemographic and Cancer-Related Characteristics
Sociodemographic characteristics included age, race, Hispanic ethnicity, level of education (percent of people in patient zip code with less than high school degree), insurance status, and rural/urban residence (county level). Charlson-Deyo score, categorized as 0 or 1?, reflecting the general health of breast cancer patients, was also available. Tumor-related factors included American Joint Committee on Cancer (AJCC) pathologic stage, grade, and histology. Estrogen receptor (ER), progesterone receptor (PR), and HER2neu status were combined to create four molecular subtype groups (ER or PR?/HER2neu-; ER and PR-/HER2neu-; ER or PR?/HER2neu?; ER and PR-/HER2neu?). 18 Treatment included surgery type and receipt of radiation and/or chemotherapy. Reporting facility type was also included.
Quality Assurance
Pilot Study Full study information was abstracted for 180 patients at 18 CoC-accredited facilities meeting the inclusion criteria (10 patients per facility), confirming feasible and valid abstraction.
Planned Reliability Study A random 5% sample of patients who received their diagnosis and/or first course treatment at multiple facilities (n = 537) was selected. Registrars at the second outside facility were asked to abstract identical information for the same patient to assess abstraction reliability. This was possible because registrars at CoC facilities are required to track patients who receive follow-up care at multiple facilities as a part of accreditation. 13 Most cancer-related care was received at the primary facility, where registrars had direct access to more complete follow-up information through that facility's medical records. In contrast, the registrar at the second facility had to request a greater number of records. A total of 1240 scans of the same type were abstracted, of which 418 were systemic imaging scans. The observed percentage agreement for surveillance versus symptom/follow-up systemic imaging was 79.4% (expected = 51.0%), while the kappa was 0.6 (Z = 11.9, p \ 0.001). This represents a lower-limit reliability estimate since, by definition, primary facilities had direct access to more complete medical information.
Statistical Analysis
The proportion of patients receiving any cancer-related and asymptomatic surveillance systemic imaging was calculated. The broadest definition of surveillance included patients receiving one or more scans for asymptomatic surveillance during follow-up, while a more conservative definition required two or more of the same scan type (head, bone, body). Among women who underwent one or more surveillance imaging scans during the follow-up period, frequencies of the imaging types performed were estimated.
The percentage of patients who received one or more surveillance systemic imaging scans was compared by molecular subtype group within each of 4 follow-up years, beginning at the start of the surveillance period (year 1: 10-24 months; year 2: 24-36 months; year 3: 36-48 months; year 4: 48-60 months). Patients were censored the year after distant recurrence, death, or when they were lost to follow-up.
Using multivariable logistic regression, we assessed factors associated with the receipt of one or more asymptomatic surveillance systemic imaging scans during followup. A missingness indicator variable was included for measures with missing information. A second model was fit predicting receipt of two or more surveillance scans. Model findings are not reported as they were consistent with models predicting one or more surveillance scans. All models were estimated with robust standard errors. Adjusted average predicted probabilities were estimated for all factors to facilitate interpretation. 19 Analyses were conducted using Stata v13 (StataCorp LP, College Station, TX, USA).
RESULTS
Of 10,838 women, 72% were under age 70 years, 41% had government-provided insurance, 71% were ER or PR?, and 19% were HER2neu ? (Table 1) .
Forty-eight percent (n = 5220) of women received one or more cancer-related systemic imaging scans during follow-up (Table 2 ). Once intent of the scan was considered, 30% of the sample (n = 3254) received one or more asymptomatic surveillance systemic imaging scans, while 12% (n = 1308) had two or more surveillance scans of the same type (body, brain, or bone). Of women who received one or more systemic imaging scans for surveillance, the majority received body imaging and/or bone scans (Fig. 1) . County-level measure of rurality and urban influence provided by NCDB, using typology published by the USDA Economic Research Service Bolded values indicate statistically significant differences, p \ 0.05
The proportion of patients who received one or more surveillance systemic imaging scans was highest during the first follow-up year, with lower proportions during subsequent years (Table 3) . During year 1, 13.5% of patients received an asymptomatic systemic imaging study, 10.0% in year 2, 8.1% in year 3, and 6.0% in year 4. The proportion of patients receiving asymptomatic systemic imaging in year 1 was lowest for patients with ER or PR?/ HER2neu-tumors (12.4%), and highest for patients with ER and PR-/HER2neu? tumors (19.2%).
Tumor and treatment, but not the majority of sociodemographic or comorbidity factors, were significantly related to receipt of one or more asymptomatic systemic imaging scans for surveillance during follow-up (Table 4 
DISCUSSION
The current growth of US healthcare expenditures is not sustainable. One attempt to control costs relies on identifying and decreasing unproven or otherwise not recommended care. For breast cancer, the use of surveillance systemic imaging for asymptomatic individuals following breast cancer treatment is considered a high value target by ASCO and the Choosing Wisely campaign. 11, 12 Consistent with prior administrative claims-based studies, [7] [8] [9] [10] we found that approximately 50% of women with stage II-III breast cancer had one or more systemic imaging scans for a cancer-related indication during a 5-year follow-up period, starting at diagnosis. However, when intent of the scan was considered, that percentage dropped; 30% of patients in our study underwent at least one systemic imaging scan in the absence of symptoms. This is consistent with the one previous study that was able to account for intent of systemic imaging. 20 We also found that only 12% of patients received two or more asymptomatic scans of the same type during the study period. If you consider true use of surveillance imaging to be the longitudinal monitoring with asymptomatic imaging over time, our data suggest that a smaller proportion of women have regular or annual advanced imaging screening for metastases than was anticipated.
Perhaps more importantly, we demonstrate that the use of systemic imaging in the absence of symptoms is primarily driven by tumor and treatment factors associated with increased risk of distant recurrence. Although breast cancer treatments are increasingly tailored to patient risk factors (e.g., molecular subtype), current follow-up guidelines and recommendations, including imaging, are not personalized. According to a growing body of evidence, risk and timing of recurrence varies, with risk being highest in the first 5 years for patients with ER/PR-tumors. 18 , 21 In our study, ER/PR-patients were more likely to have asymptomatic imaging for surveillance (regardless of HER2neu status) than ER/PR? patients, suggesting recurrence risk may play a role in clinicians' decision making regarding systemic imaging for asymptomatic surveillance. Findings further suggest that patients were more likely to receive systemic imaging earlier in the course of follow-up, especially during the first year when the risk of recurrence and patient anxiety may be highest. 18, 21 Such tailored use of asymptomatic imaging is conceptually consistent with the Choosing Wisely aim to improve quality of care, which includes providing care that is personalized and equitable. 22 The tailoring of surveillance may also represent physician uncertainty about the optimal follow-up approach, given limitations around the data supporting current follow-up imaging recommendations. Current guideline recommendations are based on randomized trials showing the detection of distant recurrence by asymptomatic systemic surveillance confers no survival or health-related quality-of-life advantage relative to less-intensive followup (provider visits with history/physical examination). [23] [24] [25] [26] [27] However, these older studies do not account for advances in systemic imaging quality and treatment effectiveness, which could result in providers ordering systemic imaging for some asymptomatic patients despite guideline recommendations.
There are several limitations to consider. First, we sampled patients at the facility level using the ratio of stage II-III patients observed nationally. Although this approach allowed for the reliable capture of the breadth of imaging practices in the US, it precludes an investigation of provider factors associated with imaging, and underrepresents higher-volume centers where a larger proportion of patients receive care. In addition, the study was limited to 2006-2007 diagnoses to allow for the collection of 5-year follow-up information. HER2neu status was not recorded consistently. Furthermore, trastuzumab was not routinely administered for patients with HER2neu ? tumors during these years, and, despite reabstraction of this information, it was missing for 7% of patients.
CONCLUSIONS
In spite of these limitations, findings indicate the use of surveillance imaging to detect asymptomatic distant recurrence in women with stage II-III breast cancer is lower than previously believed. Women who do receive imaging tend to be at highest risk of recurrence, suggesting that clinicians are tailoring their recommendations for use of surveillance imaging based on their perceptions of patients' recurrence risk. Future efforts should focus on studying the effectiveness of routine surveillance imaging in subgroups of patients thought to be at increased risk of recurrence, to determine whether the clinical practices observed in our study are warranted. Until such data are available, we should continue efforts to decrease utilization of surveillance systemic imaging.
